分区生存模型在药物经济学评价中的应用简介及实例解析

刘新义; 谭重庆; 曾小慧; 彭六保; 万小敏<sup>*</sup>

引用本文:	刘新义,谭重庆,曾小慧,彭六保,万小敏.分区生存模型在药物经济学评价中的应用简介及实例解析[J].中国现代应用药学,2019,36(24):3090-3093.
	LIU Xinyi,TAN Chongqing,ZENG Xiaohui,PENG Liubao,WAN Xiaomin.Introduction of Partitioned Survival Model in Pharmacoeconomics Evaluation and Case Analysis[J].Chin J Mod Appl Pharm(中国现代应用药学),2019,36(24):3090-3093.

【打印本页】【HTML】【下载PDF全文】【查看/发表评论】【EndNote】【RefMan】【BibTex】

←前一篇|后一篇→

过刊浏览高级检索

本文已被：浏览 5237次下载 1898次	码上扫一扫！
分享到：微信更多字体:加大+\|默认\|缩小-
分区生存模型在药物经济学评价中的应用简介及实例解析
刘新义¹, 谭重庆¹, 曾小慧², 彭六保¹, 万小敏¹
1.中南大学湘雅二医院药学部, 长沙 410011;2.中南大学湘雅二医院PET-CT中心, 长沙 410011

摘要:

目的阐述分区生存模型的概念和基本构建方法，为中国转移性肿瘤疾病药物经济学评价的进一步研究提供参考。方法结合转移性肾细胞癌治疗方案药物经济学评价实例，阐述分区生存模型在药物经济学评价中的应用及构建方法。结果转移性肾细胞癌的自然转归符合分区生存模型基本原理，模型可划分为3种互不相容的生存状态，个体患者数据重建、生存分布函数参数的计算及各周期各状态患者人数的计算是建模的关键。结论分区生存模型适用于转移性肿瘤疾病的药物经济学评价。

关键词: 药物经济学分区生存模型 Markov模型敏感度分析个体患者数据

DOI：10.13748/j.cnki.issn1007-7693.2019.24.018

分类号:R956

基金项目:国家自然科学基金项目（71874209，81603081）；湖南省卫生计生委科研计划课题项目（B20180045）

Introduction of Partitioned Survival Model in Pharmacoeconomics Evaluation and Case Analysis

LIU Xinyi¹, TAN Chongqing¹, ZENG Xiaohui², PENG Liubao¹, WAN Xiaomin¹

1.The Second Xiangya Hospital of Central South University, Department of Pharmacy, Changsha 410011, China;2.The Second Xiangya Hospital of Central South University, PET-CT Center, Changsha 410011, China

Abstract:

OBJECTIVE To introduce the basic concepts and construction method of partitioned survival model aimed at providing methodological reference for the further study of health economic evaluation of metastatic cancer in China. METHODS The application and construction method of partitioned survival model in pharmacoeconomics were described with the example of economic evaluation of the treatments of metastatic renal cell carcinoma. RESULTS The natural outcome of metastatic renal cell carcinoma conformed to the basic principle of the partitioned survival model. The model could be divided into three incompatible living states. The keys to modelling included reconstruction of individual patients data, estimation of the parameters of survival distributions, and estimation of the number of patients in each state of each cycle. CONCLUSION The partitioned survival model is suitable for health economic evaluation of treatments of metastatic cancer.

Key words: pharmacoeconomics partitioned survival model Markov model sensitivity analysis individual patient data